David A. Mankoff

This study uses [11C]glutamine PET to analyze glutamine metabolism in breast cancer mouse models, revealing subtype-specific metabolic differences and the impact of GLS1 inhibition.

This study identifies SOX5 as a key factor enabling residual breast cancer cells to maintain dormancy through endochondral ossification, improving recurrence-free survival.

This study shows that inhibiting glutaminase and xCT in TNBC disrupts redox balance, enhances chemotherapy efficacy, and can be monitored non-invasively using PET.